U.S.-based medical device manufacturer Verrix has landed $8 million in the first close of its latest Series B financing.
The round brings Verrix’s total funding to $17.5 million.
With this capital raised, Verrix will be able to complete its development operations, regulatory submission, and commercialisation of its Verrix EVA biological indicator (BI) system.
Verrix expects the first BI system based on its technological advancements to be introduced in 2019.